SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Altisent C.)
 

Sökning: WFRF:(Altisent C.) > Non-genetic risk fa...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00003898naa a2200469 4500
001oai:lup.lub.lu.se:5df5bd9f-515a-488c-a18d-0af3bce09042
003SwePub
008160404s2010 | |||||||||||000 ||eng|
0247 a https://lup.lub.lu.se/record/15951562 URI
0247 a https://doi.org/10.1111/j.1365-2516.2010.02231.x2 DOI
040 a (SwePub)lu
041 a engb eng
042 9 SwePub
072 7a art2 swepub-publicationtype
072 7a ref2 swepub-contenttype
1001 a Astermark, Janu Lund University,Lunds universitet,Klinisk koagulationsmedicin, Malmö,Forskargrupper vid Lunds universitet,Clinical Coagulation, Malmö,Lund University Research Groups4 aut0 (Swepub:lu)medf-jas
2451 0a Non-genetic risk factors and the development of inhibitors in haemophilia: a comprehensive review and consensus report.
264 c 2010-08-24
264 1b Wiley,c 2010
520 a Summary. The development of inhibitors to the infused factor in patients with haemophilia is a serious clinical problem. Recent evidence suggests that alongside the strong genetic contribution to inhibitor formation, there are a number of non-genetic factors - perceived by the immune system as danger signals - which promote formation of inhibitors. This study provides a comprehensive review of clinical studies relating to these factors and also presents a survey of opinion concerning their importance and clinical influence, conducted among the members of the European Haemophilia Treatment Standardisation Board (EHTSB). Taken together, this information highlights the lack of robust data concerning the influence of several non-genetic risk factors on inhibitor development, and an urgent need for prospective, well-conducted studies that adhere to recommendations made by the European Medicines Agency (EMEA) for studying inhibitors. Based on current literature, the EHTSB formulated consensus recommendations. It is desirable to minimize intensive treatment wherever possible, given the clinical situation. Prophylaxis should be offered to all children, although we still need to determine optimal dosing with respect to inhibitor development, and age for starting treatment. Vaccinations should be given subcutaneously and concomitant factor concentrate infusions avoided. According to the board, there is no evidence in the literature supporting suggestions that the type of concentrate influences inhibitor risk; but all patients should be monitored during their first exposures. Furthermore, there is no evidence to support an association between pregnancy-related issues, breast feeding and treatment-related factors (e.g. route of administration, or use of blood components) and inhibitor development.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Hematologi0 (SwePub)302022 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Hematology0 (SwePub)302022 hsv//eng
7001 a Altisent, C4 aut
7001 a Batorova, A4 aut
7001 a Diniz, M J4 aut
7001 a Gringeri, A4 aut
7001 a Holme, P A4 aut
7001 a Karafoulidou, A4 aut
7001 a Lopez-Fernández, M F4 aut
7001 a Reipert, B M4 aut
7001 a Rocino, A4 aut
7001 a Schiavoni, M4 aut
7001 a von Depka, M4 aut
7001 a Windyga, J4 aut
7001 a Fijnvandraat, K4 aut
7102 a Klinisk koagulationsmedicin, Malmöb Forskargrupper vid Lunds universitet4 org
7730 t Haemophiliad : Wileyg May 4, s. 747-766q May 4<747-766x 1351-8216
8564 u http://www.ncbi.nlm.nih.gov/pubmed/20398077?dopt=Abstracty FULLTEXT
8564 u http://dx.doi.org/10.1111/j.1365-2516.2010.02231.xy FULLTEXT
8564 u https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1365-2516.2010.02231.x
8564 8u https://lup.lub.lu.se/record/1595156
8564 8u https://doi.org/10.1111/j.1365-2516.2010.02231.x

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy